DIA: Driving Insights to Action
Science:Life Sciences
As the Director of CDER's Office of Generic Drugs' Clinical Safety Surveillance Staff, Dr. Howard Chazin leads a multidisciplinary team of pharmacists, medical officers and data analysts to identify and assess emerging complex safety issues related to generic drugs. “Generic drugs provide considerable cost savings. They also enhance the availability of quality medications to the American public,” he explains. “The American public should have confidence in generic drugs.”
GPP Experts Explain Authorship Algorithm
"Dossier in the Cloud" Democratizing Global Access
DIA: A Place Where You Can Make a Difference
Autumn’s Leukemia Story: Regimens, Recovery, and Realizations
Retiring TGA Head Maps Australia’s Post-Pandemic Future
Patient Engagement: Evolution of Who Knows What, Part 2
Patient Engagement: Evolution of Who Knows What, Part 1
Australian Clinical Trials Alliance Part 2 – Future Projections
ANVISA Explains Innovative Online Optimized Assessment Project
Australian Clinical Trials Alliance Part 1 – Current Perceptions
Looking Back and Ahead: Translational Science Advances Impacting Patient Care
Rwanda Welcomes African Medicines Agency Home
Will Technology Solve the Research “People Problem”?
Why Trans/Nonbinary Research Benefits All Communities
Digital Revolutionizing Data-Driven Reimbursement
China Sets New Record for Local Drug Approvals in 2021
WHO Pilot Formalizes CSA Process to Assist Developers
Medication Errors Emerge as Global Patient Safety Issue
What We Are Missing by Not Including ”Who?”
Cancer Data Ecosystem Powering Moonshot Relaunch
Create your
podcast in
minutes
It is Free
Short Wave
Unexplainable
Speaking of Psychology
Stuff To Blow Your Mind
The Science of Life with Dr. Raven Baxter